ArticleDermatology and therapy2026
Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the Kingdom of Saudi Arabia.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia areata (AA), an autoimmune disease, causes hair loss on the scalp, face, and body, with a prevalence of approximately 2% in the Middle East. AA is associated with significant impacts to patient quality of life (QoL). This study described dermatologist perceptions and experiences treating AA in the Kingdom of Saudi Arabia (KSA) while new treatments were introduced, and examined patient disease burden and unmet treatment need.
methodsData were analyzed from the Adelphi Real World AA Disease Specific Programme™, conducted September 2022-March 2023. Dermatologists rated their agreement with statements on diagnosing/managing AA and provided clinical and treatment information for four patients (mild/moderate AA: one each; severe/very severe AA: two). A subset of these patients completed the SKINDEX-16, Hospital Anxiety and Depression Scale (HADS), and the Work Productivity and Activity Impairment-AA (WPAI-AA) questionnaires. Analyses were stratified by percent scalp hair loss (SHL).
resultsA total of 50 dermatologists and 185 patients were included. Most dermatologists reported severe AA was difficult to treat owing to lack of effective therapies. A median of 51.5% SHL was reported as typical of severe AA. Impact of AA on patient QoL was the most frequently reported factor informing disease severity. Overall, 52.4% of patients had severe or very severe AA (as assessed by their physician). Approximately one-third of patients had abnormal anxiety and depression scores as measured by HADS. Patients with ≤ 20% SHL generally had lower mean Skindex-16 scores (impact of AA on QoL). Patients with ≥ 50% SHL reported greater work and activity impacts on the WPAI-AA. Most patients were receiving their first AA treatment, with the most common treatments differing by SHL category. Healthcare resource utilization and costs were greater among patients with ≥ 50% SHL.
conclusionsIn the KSA, the burden of AA extends beyond SHL to include both mental health and economic burdens, highlighting the need for effective treatments.
Indexed as
Identifiers
42601567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.